Abstract
Chronic myeloid leukemia, characterized by the BCR-ABL fusion gene, still presents deficiencies in patient treatment, as in other kinds of cancer. Chemoresistance is one of the many challenges that need to be addressed in order for a therapy to succeed against this disease. The identification of all molecular mechanisms responsible for promoting and keeping of a multiple drug resistant ph…